BioNTech could start producing malaria and tuberculosis vaccines in Rwanda and Senegal, the company said after the presidents of the two African countries met with with EU Commission chief Ursula von der Leyen and BioNTech CEO Ugur Sahin in Berlin on Thursday.
The German pharma giant is developing malaria and tuberculosis jabs based on the same mRNA technology used to make in-demand COVID-19 shots, BioNTech said.
At the Berlin meeting with Sahin and Ursula von der Leyen, Rwanda’s Paul Kagame and Senegal’s Macky Sall discussed setting up facilities to use this technology in Africa, which currently imports 99% of its vaccines and is limited to a yellow fever inoculation producer in Senegal.
New vaccines thanks to COVID-19 profits
BioNTech announced in July it would start developing malaria and tuberculosis vaccines with the first phase funded from profits gained by the global sale of its COVID-19 vaccine.